Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Nonalcoholic Steatohepatitis With Liver Fibrosis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment

NCT04634149
View directory record Official record
Conditions
Moderate Liver Impairment, Severe Liver Impairment
Interventions
BMS-986036
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Jul 24, 2026, 4:39 AM EDT
Terminated Phase 2 Interventional Results available

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

NCT03059446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
Interventions
Cenicriviroc
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
41
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03449446
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SEL, FIR, CILO, Placebo to match FIR, Placebo to match CILO, Placebo to match SEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
81
States / cities
Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Jul 24, 2026, 4:39 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects

NCT05604287
View directory record Official record
Conditions
Healthy Participants
Interventions
ID119031166M, Placebo
Drug
Lead sponsor
IlDong Pharmaceutical Co Ltd
Industry
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

NCT04483947
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
16
States / cities
Chula Vista, California • La Mesa, California • Montclair, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis (NASH) With Metformin

NCT00063232
View directory record Official record
Conditions
Hepatitis
Interventions
Metformin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Jul 24, 2026, 4:39 AM EDT
Terminated Phase 3 Interventional Results available

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

NCT02548351
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic Acid, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis

NCT02217475
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Cenicriviroc, Placebo
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Jul 24, 2026, 4:39 AM EDT
Not listed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

NCT03205345
View directory record Official record
Conditions
Decompensated Cirrhosis
Interventions
Emricasan (25 mg), Emricasan (5 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
76
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Jul 24, 2026, 4:39 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

NCT04849728
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
IVA337, Placebo
Drug
Lead sponsor
Inventiva Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
194
States / cities
Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 24, 2026, 4:39 AM EDT
Active, not recruiting Not applicable Interventional

A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG)

NCT04820036
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH), Endoscopic Sleeve Gastroplasty, Non-alcoholic Fatty Liver Disease (NAFLD), Endoscopic Ultrasound, Liver Function, Obesity, Liver Fibroses
Interventions
Insulin Resistance, Quality of Life Assessment, Liver Function Test, Radiologic features of NASH, Serologic features of NASH
Diagnostic Test · Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

NCT05623189
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Interventions
HTD1801, Placebo
Drug
Lead sponsor
HighTide Biopharma Pty Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
43
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH

NCT02279524
View directory record Official record
Conditions
Fatty Liver, Non-Alcoholic Steatohepatitis, Liver Diseases, Liver Fibroses
Interventions
Aramchol
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
Chula Vista, California • Los Angeles, California • Pasadena, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

NCT03656068
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fatty Liver, Fibrosis, Liver, Compensated Cirrhosis
Interventions
Nitazoxanide 500mg BID
Drug
Lead sponsor
Pinnacle Clinical Research, PLLC
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

NCT00013598
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05809934
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

NCT02686762
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fibrosis, Liver Diseases
Interventions
Emricasan (5 mg), Emricasan (50 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
83
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 3 Interventional

Development of a Breath Test for Monitoring Patients With Liver Disease

NCT00244569
View directory record Official record
Conditions
Fatty Liver, Cirrhosis
Interventions
13C-Methacetin, Breath ID Machine
Drug · Device
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2017 · Synced Jul 24, 2026, 4:39 AM EDT
Terminated Phase 1 Interventional

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

NCT05864391
View directory record Official record
Conditions
Steatohepatitis
Interventions
AZD7503
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
9
States / cities
Chandler, Arizona • Montclair, California • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 24, 2026, 4:39 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT05648214
View directory record Official record
Conditions
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions
ALN-PNP, Placebo (PB)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
6
States / cities
Glendale, California • Los Angeles, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 24, 2026, 4:39 AM EDT
Active, not recruiting Not applicable Interventional

Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD

NCT04861571
View directory record Official record
Conditions
NAFLD
Interventions
Dietary intervention with very low calorie diet (VLCD), Control Arm
Dietary Supplement · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 24, 2026, 4:39 AM EDT
Completed Phase 2 Interventional Results available

Treating Nonalcoholic Steatohepatitis With Pioglitazone

NCT00062764
View directory record Official record
Conditions
Hepatitis
Interventions
Actos (Pioglitazone)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Jul 24, 2026, 4:39 AM EDT
Active, not recruiting No phase listed Observational

Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes

NCT04595474
View directory record Official record
Conditions
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes, Cirrhosis, Liver
Interventions
Transient Elastography
Device
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 24, 2026, 4:39 AM EDT
Completed No phase listed Observational

Impact of Muscle Insulin Resistance on the Pathogenesis of Non Alcoholic Steatohepatitis

NCT01324414
View directory record Official record
Conditions
Non Alcoholic Fatty Liver Diseases (NAFLD)
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 10, 2016 · Synced Jul 24, 2026, 4:39 AM EDT